secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001193125-26-003467
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen elects Martin D. Madaus as Chair, succeeding Tony Hunt effective Mar 13, 2026
--------------------------------------------------------------------------------

- Tony Hunt retires as Executive Chair and Board member effective March 13, 2026; will serve as advisor through March 2027.
- Dr. Martin D. Madaus, a director since February 2023, elected as Chair of the Board effective March 13, 2026.
- Madaus brings 36 years of bioprocessing industry experience; formerly Chairman, President and CEO of Millipore.
- The succession was previously disclosed in Repligen's June 14, 2024 8-K filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312526003467/0001193125-26-003467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312526003467/rgen-20260106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-003467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer